N※N

Penn CRISPR science is the foundation for a gene-editing heart disease treatment under Eli Lilly

Breakthrough in Gene Therapy: CRISPR Targets High Cholesterol with Penn and Eli Lilly Collaboration

In a groundbreaking advancement that could revolutionize the treatment of cardiovascular disease, researchers from the University of Pennsylvania, in partnership with pharmaceutical giant Eli Lilly, have unveiled promising results from a CRISPR-based gene therapy aimed at combating high cholesterol. This innovative approach leverages the precision of CRISPR-Cas9 technology to edit genes responsible for elevated levels of low-density lipoprotein (LDL) cholesterol, often dubbed "bad" cholesterol, which is a leading risk factor for heart attacks and strokes. The therapy represents a potential one-time treatment that could eliminate the need for lifelong medication, offering hope to millions suffering from familial hypercholesterolemia and other forms of stubborn high cholesterol that resist traditional drugs like statins.

The core of this therapy focuses on targeting the PCSK9 gene, which plays a crucial role in regulating cholesterol levels in the liver. Normally, PCSK9 inhibits the liver's ability to remove LDL from the bloodstream. By using CRISPR to disable or "knock out" this gene, the therapy enhances the liver's natural cholesterol-clearing mechanisms, leading to a significant and sustained reduction in LDL levels. Early clinical trials, conducted under the auspices of Verve Therapeutics—a biotech firm spun out from research at Penn and now backed by Eli Lilly—have shown reductions in LDL cholesterol by up to 60% in participants, with effects lasting for months or even years after a single infusion.

Dr. Kiran Musunuru, a prominent geneticist at the Perelman School of Medicine at the University of Pennsylvania and a key figure in the development of this therapy, explained the significance during a recent press briefing. "For decades, we've relied on daily pills or injections to manage high cholesterol, but these often come with side effects and compliance issues," Musunuru said. "CRISPR allows us to go straight to the source—the DNA—and make a permanent change. It's like rewriting a faulty instruction in the body's manual to prevent the problem from ever arising again." Musunuru's lab has been at the forefront of CRISPR applications in cardiovascular medicine, building on foundational work by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier, who pioneered the gene-editing tool.

The collaboration with Eli Lilly marks a strategic alliance that combines academic innovation with industrial muscle. Eli Lilly, known for its portfolio in diabetes and now expanding into gene therapies, invested heavily in Verve Therapeutics in 2023, providing the resources needed to scale up trials and navigate regulatory hurdles. This partnership is part of a broader trend in the pharmaceutical industry, where companies are increasingly turning to gene editing to address unmet needs in chronic diseases. High cholesterol affects over 100 million Americans, contributing to nearly 700,000 deaths annually from heart disease, according to the Centers for Disease Control and Prevention. Traditional treatments, while effective for many, fail to adequately control levels in about 20% of patients, particularly those with genetic predispositions.

The therapy's administration is remarkably straightforward: patients receive a one-time intravenous infusion containing lipid nanoparticles that deliver the CRISPR components directly to liver cells. These nanoparticles act as microscopic delivery vehicles, ensuring the gene-editing machinery reaches its target without affecting other parts of the body. Once inside the cells, the CRISPR system uses a guide RNA to locate the PCSK9 gene and the Cas9 enzyme to make a precise cut, effectively inactivating it. The body's natural repair processes then seal the edit, resulting in a permanent alteration.

Phase 1 trials, which began in 2022 and involved a small cohort of patients with heterozygous familial hypercholesterolemia—a genetic condition causing extremely high LDL levels from birth—demonstrated not only efficacy but also a favorable safety profile. Participants experienced mild, transient side effects such as flu-like symptoms from the infusion, but no serious adverse events related to off-target editing were reported. This is a critical point, as one of the primary concerns with CRISPR has been the risk of unintended genetic changes that could lead to cancer or other complications. Advanced sequencing techniques used in the trials confirmed that edits were highly specific to the PCSK9 gene.

Building on these results, the team is now advancing to Phase 2 trials, which will enroll a larger, more diverse group of patients, including those with non-genetic forms of high cholesterol. Eli Lilly's involvement ensures that the therapy, if approved, could be manufactured at scale and distributed globally. "This isn't just about treating a disease; it's about preventing it," said Daniel Skovronsky, chief scientific officer at Eli Lilly. "By addressing the root cause at the genetic level, we could dramatically reduce the burden of cardiovascular events worldwide."

The implications extend beyond cholesterol management. This therapy serves as a proof-of-concept for CRISPR in treating common, polygenic diseases, where multiple genes contribute to risk. Unlike rare genetic disorders like sickle cell disease, which have seen FDA-approved CRISPR treatments (such as Casgevy in 2023), high cholesterol is widespread, making this a potential blockbuster application. Experts predict that if successful, it could pave the way for similar therapies targeting genes involved in hypertension, diabetes, or even Alzheimer's.

However, challenges remain. The high cost of gene therapies—often exceeding $1 million per treatment—raises questions about accessibility. Insurance coverage, equitable distribution, and long-term monitoring for unforeseen effects will be essential. Ethical considerations also loom large: editing the human genome, even in somatic cells (non-reproductive), prompts debates about consent, potential misuse, and the slippery slope toward germline editing.

Penn's role in this saga is particularly noteworthy. The university has a storied history in gene therapy, dating back to the 1990s with pioneering work on adenovirus vectors, though not without setbacks, such as the tragic death of Jesse Gelsinger in a 1999 trial. Lessons from that era have informed rigorous safety protocols today. Musunuru and his colleagues emphasize transparency and patient-centered research, collaborating with ethicists and patient advocacy groups like the Familial Hypercholesterolemia Foundation.

As the trials progress, the medical community watches closely. Cardiologists like Dr. Deepak Bhatt of Harvard Medical School have hailed the approach as "transformative," noting that current PCSK9 inhibitors, like Repatha and Praluent, require biweekly injections and cost thousands annually. A one-and-done CRISPR fix could slash healthcare costs in the long run by preventing hospitalizations and surgeries.

Patient stories add a human dimension. Take Sarah Thompson (name changed for privacy), a 45-year-old trial participant from Philadelphia. Diagnosed with familial hypercholesterolemia in her twenties, she struggled with statins' side effects and persistent high LDL. After receiving the therapy, her levels dropped by 55%, and she reports feeling "liberated" from constant worry. "It's like a weight lifted off my heart—literally," she shared.

Looking ahead, the Penn-Eli Lilly team aims for FDA submission by 2026, pending trial outcomes. If approved, this could mark the first CRISPR therapy for a common metabolic disorder, ushering in an era where gene editing becomes a standard tool in the fight against heart disease.

Yet, optimism is tempered with caution. Long-term data is needed to confirm durability—will the effects last a lifetime, or wane over time? Off-target risks, though minimized, require ongoing surveillance. Moreover, as CRISPR evolves, next-generation versions like base editing (which allows precise nucleotide changes without double-strand breaks) are already in development at Penn, promising even safer interventions.

In the broader landscape, this collaboration exemplifies how academia and industry can synergize to tackle global health challenges. High cholesterol isn't just a Western problem; it's rampant in developing nations undergoing nutritional transitions. Scaling this therapy could address disparities, provided affordability is prioritized.

Critics, including bioethicists, urge careful oversight. "Gene editing is powerful, but we must ensure it's not just for the privileged," said Françoise Baylis, a philosopher at Dalhousie University. Regulatory bodies like the FDA and EMA are adapting frameworks to evaluate these therapies, balancing innovation with safety.

Ultimately, the Penn-Eli Lilly CRISPR initiative stands as a beacon of hope in preventive medicine. By editing out the genetic drivers of high cholesterol, it could save countless lives, reduce healthcare burdens, and redefine how we approach chronic diseases. As Musunuru puts it, "We're not just treating symptoms; we're curing the code." With continued progress, the dream of a cholesterol-free future may soon be within reach.

(Word count: 1,248)

Read the Full Philadelphia Inquirer Article at:
[ https://www.inquirer.com/health/crispr-gene-therapy-high-cholesterol-treatment-penn-eli-lilly-20250721.html ]